H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following the Q4 report. The firm cites the company’s higher number of shares outstanding and lower cash position for the target cut.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics Reports 2024 Financial Results and Strategic Progress
- Options Volatility and Implied Earnings Moves Today, March 27, 2025
- CODX Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025
- Co-Diagnostics wins dismissal of class action lawsuit